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OBJECTIVE: Use of cardiac devices has been increasing
rapidly along with concerns over their safety and
effectiveness. This study used hospital administrative
data to assess cardiac device implantations in the
United States, selected perioperative outcomes, and
associated patient and hospital characteristics.
METHODS: We screened hospital discharge abstracts
from the 1997–2004 Healthcare Cost and Utilization
Project Nationwide Inpatient Samples. Patients who
underwent implantation of pacemaker (PM), automatic
cardioverter/defibrillator (AICD), or cardiac resynchroni-
zation therapy pacemaker (CRT-P) or defibrillator (CRT-D)
were identified using ICD-9-CM procedure codes. Out-
comes ascertainable from these data and associated
hospital and patient characteristics were analyzed.
MEASUREMENTS AND MAIN RESULTS: Approximate-
ly 67,000 AICDs and 178,000 PMs were implanted in
2004 in the United States, increasing 60% and 19%,
respectively, since 1997. After FDA approval in 2001,
CRT-D and CRT-P reached 33,000 and 7,000 units per
year in the United States in 2004. About 70% of the
patients were aged 65 years or older, and more than
75% of the patients had 1 or more comorbid diseases.
There were substantial decreases in length of stay, but
marked increases in charges, for example, the length of
stay of AICD implantations halved (from 9.9 days in
1997 to 5.2 days in 2004), whereas charges nearly
doubled (from $66,000 in 1997 to $117,000 in 2004).
Rates of in-hospital mortality and complications fluctu-
ated slightly during the period. Overall, adverse out-
comes were associated with advanced age, comorbid
conditions, and emergency admissions, and there was
no consistent volume–outcome relationship across dif-
ferent outcome measures and patient groups.
CONCLUSIONS: The numbers of cardiac device implan-
tations in the United States steadily increased from
1997 to 2004, with substantial reductions in length of
stay and increases in charges. Rates of in-hospital
mortality and complications changed slightly over the
years and were associated primarily with patient frailty.
KEY WORDS: pacemaker; implantable cardioverter-defibrillator; cardiac
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acemakers (PMs), automatic implantable cardioverter-
defibrillators (AICDs), and cardiac resynchronization
therapy systems (CRTs) are medical devices that regulate
cardiac rate and rhythm and coordinate myocardial contrac-
tion.
1 Overall, these cardiac devices have been shown to
improve symptoms, quality of life, and survival,
2,3 fueling
increasing enthusiasm for their use.
4–8 The increased use,
along with concerns about safety and effectiveness of the
devices and the financial incentives associated with their use,
has increased the need for data to track utilization and
outcomes.
Multiple sources of data on cardiac devices exist. First,
clinical trials are continually being conducted to study new
indications and technologies.
3,9–13 Second, reports of case
series and retrospective reviews of medical records at local
institutions offer lessons learned from practice about operative
procedures and prevention of complications.
14–18 Third, device
registries have been established to collect information on
devices, operators, and implantation techniques, as well as
on some aspects of outcomes.
19 For example, the Center for
Medicare & Medicaid Services (CMS) established an AICD
registry in January 2005 and required hospitals to submit
data on every implantation for Medicare payment.
20,21 Fourth,
the Food and Drug Administration (FDA), through MedSun
and other reporting mechanisms, collects data from operators
and manufacturers on device flaws, malfunctions, and ad-
verse events, and issues advisories and recalls.
22–26 Fifth,
surveys of operators and manufacturers have been conducted
to monitor use in the Unites States
4,5,27 and worldwide.
28
Lastly, administrative data or hospital claims data have been
used to track utilization in broad patient populations.
6,7
Each of these data sources has advantages and weakness.
Clinical trials provide robust data on efficacy, but are limited
by their choice of patients and clinical settings. Case reports
and retrospective reviews are rooted in real experience, but are
limited in generalizability and by the size of observation sets.
Registries usually have narrow focuses, such as on device
flaws and malfunction. FDA voluntary reports are limited to
what is voluntarily reported. Although lacking in clinical
details and susceptible to coding errors, administrative data
have several advantages over other data sources: primarily
large size and nationwide coverage.
29 Administrative data-
based analysis is a convenient and efficient method when
properly approached and can provide valuable information to
supplement surveys, registries, case series, and clinical trials
to study utilization, patient and hospital characteristics,
patient outcomes, and associated factors.
13This study explores the use of nationwide administrative
data to assess the incidence of PM, AICD and CRT implanta-
tions, patient and hospital characteristics, selected peri-
operative outcomes, and relationships between them for the
period 1997–2004. This study does not address clinical
indications or the clinical benefits of the devices because of
the nature of the data but rather focuses on nationwide
utilization, characteristics and outcomes ascertainable from
administrative data to provide a comprehensive scan of
cardiac device utilization in the United States and pave the
way for refined analyses that focus on specific clinical
issues.
METHODS
Data and Variables
The primary source of data for this study was the 1997–2004
Healthcare Cost and Utilization Project (HCUP) Nationwide
Inpatient Samples (NIS) developed by the Agency for Health-
care Research and Quality (AHRQ).
30 Each annual sample
contained about 8 million uniform hospital discharge
abstracts from more than 900 short-term general hospitals
across more than 30 participating states, approximating a
20% stratified sample of nonfederal acute care hospitals in
the United States. NIS includes variables on source and type
of admission, 15 diagnosis codes as classified in the Interna-
tional Classification of Diseases, 9th Edition, Clinical Modifi-
cation (ICD-9-CM), 15 ICD-9-CM procedure codes, procedure
days from admission, discharge status, length of stay (LOS),
total charges, patient demographic characteristics, insurance
coverage, and a few hospital characteristic variables (e.g.,
hospital procedure volume, size, ownership, and location).
The database also included sampling weights and design
variables for generating national estimates.
Three additional variables—costs, comorbidities, and hos-
pital volume—were created based on variables from HCUP
data. Hospital-specific cost-to-charge ratios, developed by
HCUP,
30 were used to convert charges to costs. The Elixhauser
method
31 was used to define 30 comorbid diseases based on
diagnosis codes. Defining hospital volume was not as straight-
forward. Despite recognition of the importance of surgeon
procedure volume,
32–34 no agreement exists as to what
constitutes high, medium, or low volume. Furthermore, be-
cause NIS does not identify surgeons, only hospital volume
could be constructed. Based on the literature and initial
exploration of the data, we summed the number of elective
total cardiac device implantations performed, including pri-
mary systems of pacemaker, CRT, and AICD, by each hospital
to categorize hospital volume. A “low-volume hospital” per-
formed fewer than 100 new cardiac device implantations; a
“high-volume hospital” performed 300 or more.
Identification of Patients with Cardiac Device
Implantation
Cardiac device implantation was identified from ICD-9-CM
procedure codes. Initial exploration showed that of 71,201
discharges with cardiac device procedure codes in the 2003
NIS, 37% had 1 code, 60% had 2, and 3% had 3 to 5 cardiac
device procedure codes. The Appendix classifies these patients
into 5 groups based on the code combination in each discharge
record, and the footnote lists all specific procedure codes. If
any uncertainty existed, a patient was placed into the “Other”
group. The validity of these codes or this grouping has not been
examined, but, given the clinical value of these procedures, it
is unlikely that the procedure would not be coded in the
discharge summary if it were performed, or, conversely, that
the procedure would be coded if it were not performed.
However, errors in choosing specific codes might occur,
therefore some misclassification of patients was expected.
Patient Outcome Measures
Three groups of outcome measures were constructed. The first
group included length of stay, hospital charges, and in-
hospital deaths, which were available from the source data.
The second group was measures of complications or adverse
events based on the AHRQ Patient Safety Indicators (PSIs).
35
The AHRQ PSIs include 20 indicators with reasonable validity,
specificity, and potential for fostering quality improvement.
Details on the development and validation of these indicators,
the variables and ICD-9-CM codes used to define these PSIs,
and the computer programs applying the PSIs to hospital
discharge data were downloaded from the AHRQ website.
35
Our analysis included the following 6 PSIs of primary concern
to patients who undergo cardiac device implantation: iatro-
genic pneumothorax (PSI 6), postoperative hemorrhage or
hematoma (PSI 9), postoperative pulmonary embolism or
deep vein thrombosis (PSI 12), infection caused by medical
care (PSI 7), postoperative sepsis (PSI 13), and accidental
puncture/laceration (PSI 15). The third group of outcome
measures was based on ICD-9-CM codes for mechanical
complications caused by PM (99601) or by AICD (99604),
recorded in the current hospitalization as a secondary
diagnosis. Finally, a composite outcome measure was created
to indicate whether a patient had any of the 7 types of
complications identified through the PSIs and the ICD-9-CM
codes for mechanical complications.
Statistical Method
National estimates on the numbers of cardiac device implanta-
tions by patient and hospital characteristics were estimated
and tabulated. The diagnoses codes were examined and
tabulated. Weighted estimates and standard errors were
calculated for patient outcome measures. Student’s t tests
were used to determine statistically significant difference
between 2 estimates when needed.
We conducted a series of multivariable regressions to
explore the relationship between patient outcomes and patient
and hospital characteristics such as patient comorbid condi-
tions and hospital volume. General linear regressions were
used to estimate the effects of patient and hospital character-
istics on continuous outcomes variables (i.e., LOS and costs),
and logistic regressions were used to estimate the effects of the
characteristics on dichotomous outcomes variables (i.e., mor-
tality and complication measures). P<0.05 and p<0.01 were
considered statistically significant and highly significant,
respectively.
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National Estimates of Cardiac Device Implantation
and Patient Characteristics
Table 1 shows the national estimates of primary PM, AICD, and
CRT systems implanted in 1997 to 2004 in the United States.
The last column presents the number of patients who had 1 or
more cardiac device procedures but could not be placed with
certainty in the first 4 groups. From 1997 through 2004 there
was a 145% increase in the yearly number of new AICD
implantations, but an increase of only 24% in pacemaker
implantations. PM implantations leveled off after 2001 and
demonstrated a small decline in 2004. New AICD implants also
leveled off a year later, after 2002. After approval by the FDA in
2001, CRT-D and CRT-P implantations increased quickly.
Table 2 displays the associated patient and hospital char-
acteristics for cardiac device implants performed in 2004.
Patients aged 65 or over accounted for 70% of CRT patients,
60% of AICD patients, and over 85% of PM patients. Three-
quarters of CRT and AICD patients were male, whereas about
half of the PM patients were male. Whites accounted for more
than half of the patients. At least 75% of the patients had 1 or
more chronic conditions. Approximately half of CRT implants
were planned admissions, whereas most AICD and PM
implants were during emergent admissions. Medicare was
billed for three-quarters of all cardiac device implants. Most
CRT and AICD implants were performed in large teaching
hospitals and hospitals that implanted more than 300 primary
PM, AICD, or CRTsystems a year. PM implants were most often
done in urban nonteaching hospitals, and equally distributed
among low, medium, and high-volume hospitals.
More than 60% of patients with a new CRT had congestive
heart failure as the principal diagnosis (table available upon
request). The proportion of patients who had congestive heart
failure as either the principal or a secondary diagnosis was
93%, 88%, 51%, 28%, and 41% in the 5 groups, respectively.
Cardiac dysrhythmias were the most frequent primary diag-
nosis for new AICD and PM implants.
Short-term Patient Outcomes following Cardiac
Device Implantations
Table 3 presents the national estimates for short-term patient
outcomes for 2004. The length of stay was about 6 days for
implanting primary PM, AICD, or CRT systems, but the
charges and costs for CRT and AICD implantation were double
that for PMs. In-hospital mortality risks were about 1% for
Table 1. National Estimates of Cardiac Device Implantation, 1997–
2004
Year CRT-D CRT-P AICD Pacemaker Other
1997 0 (0) 0 (0) 26,922
(2,333)
144,765
(5,416)
50,918
(2,735)
1998 0 (0) 0 (0) 28,260
(2,255)
147,695
(5,949)
41,387
(1,955)
1999 0 (0) 0 (0) 32,944
(3,168)
155,182
(6,438)
46,595
(2,711)
2000 0 (0) 0 (0) 39,334
(2,698)
164,845
(6,054)
49,488
(2,436)
2001 0 (0) 0 (0) 47,962
(3,988)
188,358
(7,096)
55,435
(3,092)
2002 1,623
(220)
734
(104)
66,528
(5,670)
188,224
(7,534)
67,593
(4,752)
2003 18,761
(1,714)
6,697
(536)
62,200
(4,190)
182,597
(6,590)
70,089
(2,643)
2004 32,737
(2,760)
7,325
(644)
66,545
(4,416)
178,816
(6,528)
60,118
(3,200)
Standard errors are in parentheses.
Table 2. Patient and Hospital Characteristics for Cardiac Device
Implantations, 2004
CRT-D CRT-P AICD Pacemaker Other
Total Sample
Size
6,752 1,509 13,577 36,818 12,370
Age (%)
0–24 –– 1 – 2
25–64 28 20 41 13 23
65–74 33 26 30 22 24
75–84 34 38 25 42 35
85+ 4 15 3 22 16
Sex (%)
Male 76 61 76 50 59
Race (%)
White 59 58 57 63 62
Black 6 6 8 6 7
Other or
missing
34 36 35 31 31
Comorbid diseases (%)
02 4 2 5 2 2 1 5 2 4
13 2 2 9 3 2 3 1 3 1
22 6 2 5 2 5 2 8 2 5
3 or more 19 20 21 27 20
Admission type (%)
Emergency 44 47 54 65 49
Planned 50 48 38 25 42
Primary payer (%)
Medicare 73 79 60 82 74
Medicaid 3 4 2 2 5
Private 21 15 30 13 18
Other 3 2 5 2 3
Hospital control (%)
Government
(n=77)
69 7 9 9
Private, not for
profit (n=417)
83 78 85 76 78
Private,
investor-
owned
(n=113)
10 13 8 15 12
Hospital size (%)
Small (N=131) 13 14 7 10 10
Medium
(N=200)
14 16 13 21 16
Large (N=284) 73 70 80 69 74
Location/teaching status (%)
Rural (N=146) 3 8 2 10 6
Urban
nonteaching
(N=312)
33 34 31 48 39
Urban teaching
(N=157)
64 58 66 43 55
New Cardiac Device Implantations per Year
<100 (N=444) 7 12 7 32 23
100–299
(N=123)
35 42 37 37 37
300 or more
(N=48)
60 46 56 30 40
“–”: The cells included fewer than 10 patients and were suppressed.
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was not statistically significant (p>0.05). The 7 measures of
complications each occurred in 1% or fewer of admissions. One
or more complications occurred in 2–4% of new implantations.
Mechanical complications were substantially more frequently
reported in hospitalizations with cardiac device procedures
that could not be determined to represent new implantations.
Table 4 highlights selected outcome estimates for AICD
patients for the years 1997 to 2003 (tables for other comes
and other patient groups available upon request). Mean LOS
decreased continuously, whereas charges nearly doubled. In-
hospital mortality rates decreased and complication rates
fluctuated slightly during the period.
Relationship between Patient Outcomes
and Patient and Hospital Characteristics
Table 5 presents the effects of patient and hospital character-
istics on in-hospital mortality for the 5 patient groups. Across the
5 patient groups, in-hospital mortality was higher among
patients who were older, under Medicare coverage, with more
comorbid diseases, or admitted through the emergency depart-
ment. Smaller hospitals appeared to have lower in-hospital
mortality rates, whereas urban teaching hospitals had higher
in-hospital mortality rates. The data did not show a consistent
volume–mortality relationship across the 5 patient groups.
Table 6 presents the effects of patient and hospital character-
istics on occurrence of complications. Again, patient frailty
indicated by advanced age and comorbidity was significant.
The relationships between other outcome measures and patient
and hospital characteristics are not presented, but are available
from the authors upon request. Overall, the estimates were
similar to that for in-hospital mortality with some notable
differences; for example, patients with more comorbid condi-
tions were less likely to suffer from iatrogenic pneumothorax.
DISCUSSION
This study showed steady increases in the number of AICDs
and PMs implanted between 1997 and 2001. After the FDA
approval of CRT in 2001, the growth in AICDs and PMs leveled
off, and CRT implantations rapidly increased. In 2004, about
33,000 new CRT-D, 7,000 CRT-P, 67,000 new AICD, and
179,000 new PM systems were implanted the United States.
A survey of physicians and device companies estimated that
153,000 PMs and 29,000 AICDs were implanted in 1997.
5 Our
administrative data-based estimates for the same year were
145,000 PMs and 27,000 AICDs, suggesting that administra-
tive data are an alternative to assessment of cardiac device
utilization in the United States.
Most patients who underwent cardiac device implantations
were elderly whites with multiple chronic conditions. Most
patients had principal diagnoses of congestive heart failure,
cardiac dysrhythmia, or conduction disorder, and almost
100% of CRT-D patients had a primary or secondary diagnosis
of congestive heart failure. These data suggest that adminis-
trative data could be used, to some extent, to assess whether
cardiac devices are implanted in patients with proper indica-
tions. Further studies could be conducted in narrowly defined
patient groups to examine patient indications.
Whereas most CRT and AICD implantations were done in
large teaching hospitals that implanted 300 or more primary
systems a year, PM implants were done more among non-
teaching and low-volume hospitals. More research could be
conducted to examine how patient characteristics and out-
comes differ by hospital type, for example, whether patient
outcomes are better in high-volume hospitals than in low-
volume hospitals.
Patients stayed in hospitals for about 5 days for AICD
implantation in 2004, a substantial decrease from 9.19 days in
1997. In the meantime, the charges and costs increased
steadily, from an average charge of $66,530 for an AICD in
1997 to $114,782 in 2004. CRT-D and AICD implantations were
substantially more costly than CRT-P and PM. These cardiac
device procedures had a substantially lower than average cost-
to-charge ratio of 0.50, suggesting that patient admissions for
cardiac device procedures might be more profitable than other
hospital admissions. The rapid diffusion, especially the increase
in CRT implantations, coupled with the profit potential, raises a
question about the proper use of these devices.
Fewer than 2% of the patients died, and fewer than 4% of
the patients had complications during hospitalization. As
expected, iatrogenic pneumothorax was substantially more
frequent in cardiac device implantations compared with that in
surgical patients, which was reported at 0.09% in 2003,
36
whereas the rates of other complications in cardiac device
patients were comparable to those in general surgical patients
as documented by the 2006 National Healthcare Quality
Table 3. In-hospital Patient Outcomes After Cardiac Device
Implantation, Unadjusted, 2004
Patient
outcomes
CRT-D CRT-P New
AICD
Pacemaker Other
Mean LOS
(days)
5.2
(0.2)
5.5
(0.2)
6.2
(0.2)
5.9 (0.1) 6.5
(0.2)
Mean charges
($1,000)
117
(6)
76 (4) 110
(5)
52 (1) 66 (2)
Mean costs
($1000)
42 (1) 28 (1) 40 (1) 19 (1) 24 (1)
In-hospital
mortality (%)
0.93
(0.12)
1.40
(0.32)
0.75
(0.08)
1.12
(0.07)
1.86
(0.16)
Iatrogenic
pneumothorax (%)
0.94
(0.14)
0.66
(0.20)
0.77
(0.08)
1.04
(0.06)
0.87
(0.08)
Postoperative
hemorrhage or
hematoma (%)
0.28
(0.06)
0.06
(0.06)
0.19
(0.04)
0.04
(0.01)
0.52
(0.08)
Postoperative
pulmonary
embolism or
deep venous
thrombosis (%)
1.17
(0.14)
1.48
(0.29)
1.13
(0.10)
0.24
(0.03)
1.80
(0.15)
Infection due
to medical care (%)
0.27
(0.06)
0.40
(0.18)
0.45
(0.05)
0.28
(0.03)
0.38
(0.06)
Postoperative
sepsis (%)
0.16
(0.05)
0.20
(0.11)
0.07
(0.03)
0.05
(0.01)
0.26
(0.06)
Accidental puncture/
laceration (%)
0.44
(0.08)
0.26
(0.13)
0.36
(0.06)
0.31
(0.04)
0.57
(0.08)
Mechanical
complication (%)
0.90
(0.14)
1.16
(0.28)
0.39
(0.06)
0.23
(0.03)
11.35
(0.49)
Any of the above
7 complications (%)
3.96
(0.32)
3.76
(0.45)
3.20
(0.19)
2.14
(0.09)
14.94
(0.54)
Standard errors are in parenthesis.
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PE, and accidental puncture were reported at 0.2%, 0.9%, and
0.4%, respectively.
36 Our analysis further showed that adverse
outcomes were mostly associated with patient frailty indicated
by advanced age, comorbidities, and emergency admission,
and associated with the complexity of device implantations
(i.e., AICDs and CRTs compared to pacemaker implantations).
Given that the patients were mostly elderly with multiple
Table 4. In-hospital Patient Outcomes After AICD Implantation, Unadjusted, 1997–2003
Patient outcomes 1997 1998 1999 2000 2001 2002 2003
Mean LOS (days) 9.9(0.4) 8.1(0.2) 8.3(0.3) 7.7(0.2) 7.4(0.2) 6.8(0.2) 6.4(0.2)
Mean Charges ($1000) 66 (2) 69 (2) 72 (2) 78 (2) 86 (3) 101 (4) 115 (4)
In-hospital mortality (%) 0.7(0.1) 0.8(0.1) 1.0(0.1) 0.9(0.1) 0.8(0.1) 1.0(0.1) 0.9(0.1)
Any of above 7 complications (%) 2.8(0.3) 2.9(0.3) 3.1(0.3) 2.3(0.2) 3.0(0.2) 3.4(0.2) 3.3(0.2)
Standard errors are in parenthesis.
Table 5. The Effects of Patient and Hospital Characteristics on
In-hospital Mortality (Odds Ratios)
CRT-
D
CRT-
P
AICD Pacemaker Other
Age (%)
25–64* Ref Ref Ref Ref Ref
65–74 0.76 0.61 0.66 0.88 1.14
75–84 1.43† 0.73 1.18‡ 1.02 1.07
85+ 2.32‡ 0.90 0.85 1.56‡ 0.96
Sex (%)
Male Ref Ref Ref Ref Ref
Female 0.68‡ 0.67 1.43‡ 0.96 0.71‡
Race (%)
White Ref Ref Ref Ref Ref
Black 0.50† 1.98† 1.04 1.24‡ 1.08
Other or missing 1.39‡ 1.23 0.94 0.93 1.05
Comorbid diseases (%)
0 Ref Ref Ref Ref Ref
1 0.47‡ 1.56 1.03 1.46‡ 1.57‡
2 1.83‡ 2.15† 1.31 1.90‡ 2.31‡
3 or more 3.96‡ 4.87‡ 2.97‡ 3.30‡ 4.27‡
Admission type (%)
Planned Ref Ref Ref Ref Ref
Emergency 1.54‡ 2.50‡ 1.72‡ 1.70‡ 1.91‡
Primary payer (%)
Private Ref Ref Ref Ref Ref
Medicare 1.01 1.17 2.64‡ 1.46‡ 1.03
Medicaid 0.93 0.23 1.43 1.08 1.11
Other 0.22 2.48 2.07‡ 1.29 1.47‡
Hospital control (%)
Government
(n=77)
Ref Ref Ref Ref Ref
Private, not for
profit (n=417)
0.71 2.40 0.78 0.94 1.09
Private, Investor-
owned (n=113)
1.00 3.04 0.79 0.72‡ 1.42‡
Hospital size (%)
Small (N=131) 0.48‡ 0.90 0.97 0.94‡ 0.72†
Medium (N=200) Ref Ref Ref Ref Ref
Large (N=284) 0.58‡ 2.32† 0.98 1.09 1.11
Location/teaching status (%)
Rural (N=146) 2.31‡ 1.79 0.46 0.96 1.05
Urban
nonteaching
(N=312)
Ref Ref Ref Ref Ref
Urban teaching
(N=157)
1.18 1.69 1.48‡ 1.22‡ 1.62‡
New Cardiac Device Implantations per Year
<100 (N=444) Ref Ref ref ref ref
100–299 (N=123) 2.22† 0.75 1.18 0.78‡ 1.05
300 or more
(N=48)
1.52 0.82 1.08 0.69‡ 0.94
*Patients age <25 were lumped into this group
†p<0.05
‡p<0.01; Ref: reference group
Table 6. The Effects of Patient and Hospital Characteristics on
Having Any Complication (Odds Ratios)
CRT-
D
CRT-
P
AICD Pacemaker Other
Age (%)0
25–64* Ref Ref Ref Ref Ref
65–74 1.08 0.79 0.79† 0.88 1.11‡
75–84 0.97 0.86 1.04 1.03 1.16†
85+ 1.09 0.45† 1.34‡ 0.86‡ 0.96
Sex (%)
Male Ref ref ref ref ref
Female 1.28† 0.64† 1.58† 1.62† 1.02
Race (%)
White Ref ref ref ref ref
Black 0.79 0.94 1.01 1.00 0.99
Other or missing 0.76† 0.83 0.99 1.06 1.08†
Comorbid diseases (%)
0 Ref ref ref ref ref
1 1.18† 0.90 0.87‡ 0.84† 1.15†
2 0.99 1.75† 0.99 0.84† 1.30†
3or more 1.31† 1.08 1.03 0.96 1.63†
Admission type (%)
Planned Ref ref ref Ref Ref
Emergency 1.09 2.14† 1.40† 0.95 1.39†
Primary payer (%)
Private Ref ref ref ref ref
Medicare 1.05 1.36 0.99† 1.23† 0.91†
Medicaid 0.88 1.68 1.12 1.05 1.02
Other 1.39 0.82 1.39† 0.97 0.96
Hospital control (%)
Government
(n=77)
Ref ref ref ref Ref
Private, not for
profit (n=417)
0.52† 0.75 0.85‡ 0.90 1.02
Private, Investor-
owned (n=113)
0.89 0.71 1.11 0.94 1.14†
Hospital size (%)
Small (N=131) 0.75‡ 1.64‡ 0.98 0.84‡ 0.91‡
Medium (N=200) Ref ref ref ref ref
Large (N=284) 1.01 0.97 1.01 1.19† 0.82†
Location/teaching status (%)
Rural (N=146) 0.92 0.88 0.16† 0.86† 1.28†
Urban
nonteaching
(N=312)
Ref ref ref ref ref
Urban teaching
(N=157)
1.06 0.82 1.15‡ 1.14† 0.85†
New Cardiac Device Implantations per Year
<100 (N=444) Ref Ref Ref Ref Ref
100–299 (N=123) 1.23 0.80 1.10 1.39† 1.16†
300 or more
(N=48)
1.59† 0.78 0.83 1.42† 0.94
Ref: reference group
*Patients age <25 were lumped into this group.
†p<0.01;
‡p<0.05
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suggest that the implantation procedures were fairly safe.
Administrative data have many limitations when used to
study a clinical intervention. Previous studies identified many
cardiac device-related complications, such as pocket hemato-
ma,
15,37,38 pocket infections,
7,38–43 iatrogenic pneumotho-
rax,
40,41 arterial puncture,
40 venous thrombosis and
stenosis,
41 electrode displacement,
40 lead dislodgements,
undersensing,
40,42 cardiac device endocarditis,
44,45 interfer-
ence by an electronic antitheft-surveillance device
46 or a
Personal Digital Assistant,
17 and twiddle-induced torsion of
leads.
41 Administrative data may not able to identify many of
these specific types of complications. The data do not capture
deaths or complications that are detected after discharge. The
data do not capture the risk associated with the experience of
t h es u r g e o n ,t y p eo fd e v i c eu s e d( s u c ha sd u a l - c h a m b e r
pacemaker or biventricular pacemaker, both of which have
different risks of complications),
47 the experience of operating
room staff, type of anesthesia used, and other clinical vari-
ables. Nevertheless, our study demonstrates that administra-
tive data provide an efficient and reliable source to track
utilization of cardiac devices, to evaluate associated patient
and hospital characteristics, and to offer valuable insights into
patient risks and outcomes after implantations.
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